With more studies emerging, GLP-1 and dual GIP/GLP-1 medications have become well-established options for those with obesity or type 2 diabetes.
A large McGill University study has found that two classes of medications commonly prescribed for type 2 diabetes, both ...
WASHINGTON, DC — Use of sodium-glucose cotransporter-2 inhibitors (SGLT2i) reduced the need for urate-lowering therapy (ULT) and gout flare therapies in people who had both type 2 diabetes (T2D) and ...
The landscape of diabetes management is undergoing a remarkable transformation. Groundbreaking research has uncovered surprising cardiovascular benefits tied to modern medications, offering new hope ...
A recent study highlights a surprising potential benefit of diabetes and obesity drugs, GLP-1 receptor agonists, in improving ...
Patients and physicians often both play a role when a patient’s treatment stalls. There are ways to prevent it.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results